Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

CLINUVEL PHARMACEUTICALS LIMITED

INVESTOR PRESENTATION - CLINUVEL PHARMACEUTICALS LIMITED

ASX:CUV

CLINUVEL PHARMACEUTICALS LIMITED

Health Care

Clinuvel Pharmaceuticals Limited (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. CUV's lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP). Former Names EpiTan Limited (EPT),28/02/2006

Read more

Market Cap

1.16b

Price at Close

$23.47

4w avg. Volume

197.58k

4w avg. Turnover

$4.33m

Announcements
announcementt+2 movementdate
  • CLINUVEL Newsletter

    Progress Report

  • -1.72%

    23 Sep 2020

-1.72%

23 Sep 2020
  • CLINUVEL Confirms AGM Date

    Notice Of Meeting

  • -1.72%

    23 Sep 2020

-1.72%

23 Sep 2020
  • Change of Director's Interest Notice

    Shareholder Details

  • -2.64%

    16 Sep 2020

-2.64%

16 Sep 2020
  • Media Release - First patient dosed in SCENESSE DNA Repair

    Progress Report · Market sensitive

  • +10.28%

    14 Sep 2020

+10.28%

14 Sep 2020
  • First patient dosed in SCENESSE DNA Repair Program

    Progress Report

  • +10.28%

    14 Sep 2020

+10.28%

14 Sep 2020
  • CLINUVEL progresses innovative DNA Repair Program

    Progress Report · Market sensitive

  • +9.80%

    09 Sep 2020

+9.80%

09 Sep 2020
  • SCENESSE in DNA Repair

    Progress Report

  • +9.80%

    09 Sep 2020

+9.80%

09 Sep 2020
  • Change of Director's Interest Notice

    Shareholder Details

  • +2.27%

    01 Sep 2020

+2.27%

01 Sep 2020
  • Proposed issue of Securities - CUV

    Issued Capital

  • +2.27%

    01 Sep 2020

+2.27%

01 Sep 2020
  • Media Release - CLINUVEL opens R&D centre in Singapore

    Progress Report

  • -0.96%

    30 Aug 2020

-0.96%

30 Aug 2020
Market Data

Current Price

$23.47

52WK HIGH

$45.88

52WK LOW

$12.92

1YR RETURN

-8.03%

1YR RETURN VS. SECTOR

-42.33%

90 DAY RETURN

-4.67%

ASX RANK

222

/2,020

SECTOR RANK

4

/47

SHARES OUTSTANDING

49.41m
ASX:CUV

CLINUVEL PHARMACEUTICALS LIMITED

Health Care

Clinuvel Pharmaceuticals Limited (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. CUV's lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP). Former Names EpiTan Limited (EPT),28/02/2006

Read more

Market Cap

1.16b

Price at Close

$23.47

4w avg. Volume

197.58k

4w avg. Turnover

$4.33m

ASX:CUV is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.